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Abstract 
Purpose: To develop and validate a new, simple, sensitive and accurate high performance liquid 
chromatographic (HPLC) method for the simulataneous determination of matrine and secnidazole in 
suppositories. 
Methods: The method involved using a SinoChoom ODS-BP C18 column (5 µm, 4.6 mm × 200 mm) 
and mobile phase consisting of acetonitrile–triethylamine (0.05 %) in 0.025 mol/L KH2PO4 (20:80, v/v). 
The flow rate was 1 mL/min and detection was monitored at 210 and 311 nm for matrine and 
secnidazole, respectively. Total run time was 10 min and the column was maintained at 35 oC.   
Results: The excipients in the suppository did not interfere with the drug peaks. Matrine was eluted at a 
retention time (RT) of 4.30 min while linearity for the quantification of drug was obtained in the 
concentration range of 10.0 - 100.0 µg/mL (r2 = 0.9991). Secnidazole was eluted at a retention time (tr) 
of 6.69 min and linearity for the quantification of the drug was obtained in the concentration range of 
10.0 - 150.0 µg/mL (r2 = 0.9993). Intra- and inter-day variations were < 1.0 % for both matrine and 
secnidazole.  
Conclusion: The developed HPLC method was validated according to International Conference on 
Harmonisation (ICH) guidelines and proved to be suitable for the simultaneous determination of matrine 
and secnidazole in suppositories. 
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Bacterial vaginosis is a common cause of 
malodorous vaginal discharge in women of 
reproductive age, occurring in up to 30 % of 
women [1]. Besides being unpleasant for patients 
when symptoms of discharge and odour occur, 
bacterial vaginosis is associated with increased 
risk of several pathological gynaecological 
conditions as well as major adverse outcomes 
during pregnancy. It is estimated that bacterial 
vaginosis is associated with a two-fold increased 
risk of pre-term birth and a six-fold increased risk 
of miscarriage [2]. Bacterial vaginosis is also 
associated with increased susceptibility to 
sexually transmitted infections, including herpes 
simplex viruses, human papillomavirus, and 
human immunodeficiency virus[3,4].  
 
Secnidazole, chemically 1-(2-hydroxypropyl)-2-
methyl-5-nitroimidazole (Fig.1), is a new second 
generation 5-nitroimidazole product [5]. It is a 
nitroimidazole antibiotic with a broad spectrum of 
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activity against anaerobic microorganisms, 
higher efficacy, fewer adverse effect and has a 
longer half-life than metronidazole. It was widely 
used for the treatment and prevention of certain 
bacterial and protozoal diseases clinically. Used 
as a single-dose oral regimen, it appears 
effective in the treatment of amebiasis, 
giardiasis, trichomoniasis, and bacterial 
vaginosis. [6,7]  
 
Matrine, chemically 7aS,13aR,13bR,13cS)- 
dodecahydro-1H,5H,10H- dipyrido [2,1- f:3′,2′,1′-
ij] [1,6] naphthyridin-10-one (Fig. 1), is an 
important ingredient extracted from Sophora 
flavescens Ait, Sophora subprostrata, and 
Sophora alopecuroides L., which are leguminous 
plants widely distributed in the northwestern 
region of China and are important Chinese 
herbal remedies. It has been proved that matrine 
is a nitrogen-containing heterocyclic , which 
belong to the quinolizidine alkaloids. It is very 
soluble in water, chloroform and benzene [8-12]. 
It has a wide range of pharmacological 
applications including anti-inflammatory, 
antiendotoxic and anticancer with no obvious 
toxicity or side effect [13].The suppository 
combining matrine and secnidazole can play 
synergistic roles for effective treatment of 
gynecological diseases. 
 
High-performance liquid chromatography (HPLC) 
has been widely used to quantitate matrine and 
secnidazole individually in preparations and 
biological samples. To the best of our 
knowledge, few HPLC methods have been 
developed in the literature for the determination 
of matrine and secnidazole in preparations 
simultaneously [14-19]. The literature was mainly 
focused on determination of the content of  
matrine and secnidazole one by one. The aim of 
this study is to develop and validate a simple, 
rapid, senstive and reproducible HPLC method to 
determine matrine and secnidazole 
simultaneously when combined in a suppository 
with the advantages of shorter retention time and 
run-time.                               
    
Figure 1: Typical chemical structure of (a) secnidazole 









Pure matrine and secnidazole used as working 
standards were received as gifts from 
Zhongzhou Pharmaceuticals Co., Ltd, 
(Zhengzhou, PR China). Acetonitrile of HPLC 
grade and other chemicals of AR grade were 
purchased from Mingshen Chemicals Co, Ltd, 
(Zhengzhou, PR China). Deionized water was 
obtained using a Milli-Q water purification system 
(Millipore, Bedford, MA, USA). All other 
chemicals were used as received without further 
purification. 
 
Preparation of matrine/secnidazole 
suppositories 
 
Matrine/secnidazole suppositories were prepared 
by fusion method. Mixtures of gelatin, glycerin 
and water (10:15:15, w/v ) were used as 
suppository bases; the mixture was placed in a 
beaker and melted by heating to 70 oC in a hot 
water bath. Secnidazole (16 g) and  matrine (4 g) 
were mixed with the molten base, poured into a 
10 holes steel suppository mold and allowed to 
solidify at room temperature. After solidification, 
the formed suppositories were removed from the 
mold, wrapped with aluminum foil, and stored in 
a desiccator with silicone in the refrigerator at 4 
oC pending further use. Each of the suppositories 
was formulated to contain 200 mg secnidazole 
and 50 mg matrine.  
 
Determination of matrine and secnidazole 
 
Chromatographic analysis was performed using 
a Shimadzu system that comprised of LC-20AT 
pump, SPD 20A UV-visible absorbance detector 
connected to Shimadzu Spin Chrome software. 
ODS-BP C18 column (5 µm, 4.6 mm×200 mm) 
was used and the sample injection was 
performed via a Rheodyne syringe.  
 
The mobile phase was a mixture of acetonitrile- 
triethylamine (0.05 %) in 0.025 mol/L KH2PO4 
(20:80, v/v). The flow rate was 1.0 mL/min. The 
mobile phase was degassed by an ultrasonic 
bath and filtered through a 0.45µm membrane 
filter under vacuum. The eluents were detected 
and quantified at 210 nm from 0 min to 5.5 min 
and at 311nm from 5.5 min to 10.0 min. The 
column was maintained at 35 oC and injection 
volume was 20 µL.  
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Preparation of standard stock solutions and 
working solutions  
 
The standard solutions of the pure drugs were 
prepared by dissolving accurately 100 mg 
matrine and 150 mg secnidazole in separate 10 
mL volumetric flasks using the mobile phase, 
respectively. The volumes were made up to the 
mark with mobile phase. Intermediate and 
working solutions were prepared by diluting stock 
solutions with the mobile phase. Calibration 
standard solutions were prepared in the 
concentration range of 10 to 100 µg/mL for 
matrine and 10 to 150µg/mL for secnidazole, and 
injected into the system in triplicate. The 
chromatogram peak area of each drug 
concentration was calculated. The regression of 
the drug concentration versus the peak area was 
obtained. 
 
Quantification of matrine and secnidazole in 
suppository  
 
Ten suppositories were accurately weighed and 
crushed to fine particles in a mortar and an 
amount equivalent to one suppository was 
transferred into a 100 mL volumetric flask. The 
mixture was dissolved and then made up to 
volume with mobile phase. It was kept in an 
ultrasonic bath for 5 min and the solution filtered 
through a 0.45 µm filter paper. Suitable aliquots 
of the filtered solution were transferred to a 
volumetric flask and made up to volume with 
mobile phase to yield concentrations of matrine 
(20.0 µg/mL) and secnidazole (80.0 µg/mL). A 20 
µL aliquot of the sample solution was injected 
into the chromatographic system three times 
under optimized chromatographic conditions. 
The peak area was measured at 210 nm from 0 
to 5.5 min and at 311 nm from 5.5 to 10.0 min for 
matrine and secnidazole, respectively. Drug 
concentrations of the samples were determined 
by interpolation from calibration plots of each 
drug previously obtained.   
 
Method validation  
 
The method was validated with parameters of 
specificity, linearity, accuracy, precision, 




Combined working solution (matrine 20.0µg/mL, 
secnidazole 80.0µg/mL), blank excipients sample 
without matrine and secnidazole, equal 
concentrations sample of combined suppository 
(matrine 20.0µg/mL, secnidazole 80.0µg/mL) 
made with above procedure were scanned from 
200nm to 400nm, and then the chromatograms 
were recorded.  
 
Linearity   
 
Matrine and secnidazole working solutions at 
eight different concentrations (The concentration 
was 10, 25, 35, 45, 55, 75 85, 100 µg/mL for 
matrine and 10, 20, 40, 50, 80, 100, 120, 150 
µg/mL for secnidazole, respectively) were 
prepared for linearity studies and injected into 
chromatographic system (n = 3). The responses 




Adequate amounts of matrine and secnidazole 
were added to gelatin and glycerin excipients to 
make three concentration levels (80, 100 and 
120 %). At each level, three determinations were 
performed and the results were recorded. 
Accuracy was expressed as percent analyte 




The  precision  of  the method  was  checked  by  
repeatability  of injection,  repeatability (intra-
day), intermediate precision (inter-day) and 
reproducibility.  Injection repeatability was 
studied by calculating percent relative standard 
deviation  (% RSD) for ten determinations each 
of peak area of matrine (20.0 µg/mL) and 
secnidazole (80.0 µg/mL) performed on the 
same day. The same solutions were injected in 




The robustness of the developed method was 
determined by carrying out the analysis, during 
which mobile phase composition (concentration 
of acetonitrile was varied by ± 5 %), flow rate and 
column temperature were altered and the peak 






From the UV-visible spectra, matrine had 
maximum absorption at 210 nm and secnidazole 
had maximum absorption at 311 nm. Thus, 210 
nm and 311 nm were selected as detection 
wavelengths. Under optimum conditions, typical 
chromatograms of matrine and secnidazole 
solutions, blank excipients sample without 
matrine and secnidazole, suppository sample are 
shown in Fig 2. The retention times of matrine 
and secnidazole at a flow rate of 1.0 mL/min 
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were 4.30 and 6.69 min, respectively. Analyte 
peaks were well resolved and free from tailing (< 
1.5 for both analytes). The excipients in the 
suppository did not interfere with the detection of 
matrine and secnidazole. 
        
    
 
 
Figure 2: Chromatograms of (a) matrine (*RT = 4.30) 
and secnidazole (**RT = 6.69); (b) blank gelatin and 





Under optimal conditions, the calibration curve 
obtained by plotting peak area against 
concentration showed linearity in the 
concentration range of 10.0 - 100.0 µg/mL for 
matrine and 10.0 - 150.0 µg/mL for secnidazole. 
The regression equations, y = 28.266x ＋ 25.017 
for matrine and y = 43.774x －12.475 for 
secnidazole were established based on the 
standard samples injected, with correlation 
coefficients of 0.9991 and 0.9993 respectively; 
where y is peak area based on three parallel 
measurements and x is the concentration (µg/ml) 
of matrine or secnidazole standard solution. The 
correlation coefficients indicate a good linear 
relationship between peak area and 




Mean recovery for matrine and secnidazole was 




The measurements of intra- and inter-day 
variability were utilized to determine the precision 
of the developed method. The relative standard 
deviation (RSD) of intra-day variation for matrine 
was 0.75 % and for inter-day variation 0.81% 
while the corresponding values for secnidazole 
were 0.69 and 0.72 %. The low values of RSD 
indicate that the method was precise. Injection 
repeatability values of matrine and secnidazole 
were 0.87 and 0.64 %, respectively. 
Reproducibility was checked by having rhe 
samples analyzed by another analyst using same 
instrument and same laboratory. There was no 
significant difference between the RSD values, 





The robustness test results for the developed 
method are as shown in Table 1. It is clear that 
there was no significant change in peak area and 
retention time of matrine and secnidazole when 
the ratio of acetonitrile, flow rate and column 
temperature were varied (p < 0.05). The results 
indicate that the developed method was 
sufficiently robust for normally expected 
variations in chromatographic conditions. 
 
Content of matrine and secnidazole in 
suppositories  
 
Matrine and secnidazole, when co-formulated in 
suppositories, were simultaneously determined 
with the proposed method. The results of the 
assay yielded 100.07 ± 0.45 % for matrine and 
99.92 ± 0.38 % for secnidazole, thus showing 
that the method was selective and accurate for 
the simultaneous determination of matrine and 
secnidazole without interference from the 




This study was essentially focused on the 
simultaneous determination of co-formulated 
matrine and secnidazole in suppositories.  
Following initrials trials to establish optimum 
conditions, a mixture of acetonitrile–triethylamine 
(0.05%) in 0.025 mol/L KH2PO4 (20:80, v/v) was  
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Analyte Variation in acetonitrile content of mobile phase 
Variation in flow 
rate (mL/min) 
Variation in column 
temperature (℃) 
19 20 21 0.9 1.0 1.2 34 35 36 
Matrine 
0.2 0.1 0.2 0.2 0.1 0.2 0.1 0.1 0.3 
19 20 21 0.9 1.0 1.2 34 35 36 
RSD (%) 
Secnidazole 
0.2 0.1 0.3 0.2 0.1 0.2 0.3 0.1 0.2 
 
selected as the optimum mobile phase for 
baseline separation and short retention time. 
Matrine and secnidazole were soluble in organic 
solvents including methanol and acetonitrile. The 
use of mobile phase as extraction reagent 
provided minimal impurities and better 
separation. 
 
The successfully validated method using HPLC 
grade solvents had short retention times and 
high peak symmetry. Therefore, it can be 
performed in any laboratory with adequate HPLC 
instrumentation for a relatively rapid and low-cost 
assay. The mobile phase system gave sharp 
peaks for matrine and secnidazole without 
interfering peaks. The retention time (RT) of 
matrine and secnidazole was 4.30 and 6.69 min, 
respectively . The method was linear over wide 
concentration ranges for matrine and 
secnidazole, indicating good correlation between 
concentration and peak area.   
 
The method was validated in terms of linearity, 
accuracy, precision and robustness according to 
ICH guidelines. Adequate resolution between 
matrine and secnidazole peaks showed the 
efficiency of the method based on its capacity to 
identify and determine each analyte at the same 
time with no interference. The method was 
robust because minor changes in the 
chromatographic parameters did not bring about 
any significant changes in peak area and 
retention time. The accuracy data show that the 




The developed method is simple, rapid, cost-
effective, highly sensitive and provides good 
reproducibility and accuracy for the simultaneous 
determination of matrine and secnidazole when 
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